Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system

[1]  J. Glanz,et al.  Safety of COVID-19 Vaccination in US Children Ages 5-11 Years. , 2022, Pediatrics.

[2]  S. Antinori,et al.  Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes. , 2022, Diabetes.

[3]  T. Shimabukuro,et al.  Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[4]  D. Shay,et al.  COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. , 2021, MMWR. Morbidity and mortality weekly report.

[5]  M. McNeil,et al.  Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines , 2021, Expert review of vaccines.

[6]  Melissa Suran.  Why Parents Still Hesitate to Vaccinate Their Children Against COVID-19. , 2021, JAMA.

[7]  M. Mehling,et al.  Smartphone-based active vaccine safety surveillance (SmartVax) at a Swiss adult vaccination clinic - a pilot study. , 2021, Swiss medical weekly.

[8]  Daniel T McMillan,et al.  COVID-19 mRNA Vaccination, ABO Blood Type and the Severity of Self-Reported Reactogenicity in a Large Healthcare System: A Brief Report of a Cross-Sectional Study , 2021, Cureus.

[9]  Rachael K. Raw,et al.  Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine , 2021, Vaccine.

[10]  M. Rämet,et al.  Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age , 2021, The New England journal of medicine.

[11]  I. Litchfield,et al.  Impact of COVID-19 on the digital divide: a rapid review , 2021, BMJ Open.

[12]  J. Newburger,et al.  Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. , 2021, JAMA cardiology.

[13]  Ziyang Feng,et al.  A comprehensive analysis of the efficacy and safety of COVID-19 vaccines , 2021, Molecular Therapy.

[14]  J. Parienti,et al.  Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study , 2021, Vaccine.

[15]  P. Dormitzer,et al.  Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.

[16]  P. Magnus,et al.  Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study , 2021, Vaccine.

[17]  David A. Drew,et al.  Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study , 2021, The Lancet Infectious Diseases.

[18]  K. Jöckel,et al.  Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers , 2021, Journal of Infection.

[19]  V. Simon,et al.  Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.

[20]  Xiaoxuan Liu,et al.  Health data poverty: an assailable barrier to equitable digital health care. , 2021, The Lancet. Digital health.

[21]  J. Moon,et al.  Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals , 2021, The Lancet.

[22]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[23]  Michael K Gould,et al.  Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. , 2012, The Permanente journal.